TD Cowen maintains Buy rating on United Therapeutics stock, citing IPF opportunity
PositiveFinancial Markets

TD Cowen has reaffirmed its Buy rating on United Therapeutics stock, highlighting the company's potential in the idiopathic pulmonary fibrosis (IPF) market. This is significant as it reflects confidence in United Therapeutics' growth prospects and innovative treatments, which could lead to improved patient outcomes and increased investor interest.
— Curated by the World Pulse Now AI Editorial System